ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.

W. Arns,1 A. Huppertz,1 T. Rath,1 S. Ziefle,1 L. Rump,1 A. Hansen,1 D. Baeumer,2 K. Budde,1 L. Lehner,1 T. Klein,1 P. Schenker.1

1SparTacus Study Group, Cologne, Germany
2Novartis Pharma GmbH, Nuernberg, Germany.

Meeting: 2016 American Transplant Congress

Abstract number: A164

Keywords: Calcineurin, Immunosuppression, Kidney transplantation, Pharmacokinetics

Session Information

Date: Saturday, June 11, 2016

Session Name: Poster Session A: Kidney: Acute Cellular Rejection

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Related Abstracts
  • Efficacy, Safety and Pharmacokinetics of Once-Daily, MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus (Prograf®) in De Novo Kidney Transplant Recipient Sub-Groups: A 2 Year Phase 3 Randomized, Double-Blind, Double-Dummy, Trial
  • Multicenter Randomized Clinical Investigation for the Safety and Efficacy of Advagraf® (Extended-Release Tacrolimus) vs. Prograf® (Twice-Daily Tacrolimus) in De Novo Korean Adult Kidney Recipients

Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx) setting. The SparTacus (NCT01649427) study was designed to evaluate the PK profile and clinical data of tacrolimus Hexal® vs. Prograf® in de novo kidney Tx recipients (KTxR).

Methods: A total of 76 de novo KTxR were randomized in this prospective, two-phase open-label study to receive either tacrolimus Hexal® (n=35) or Prograf® (n=41), both in combination with enteric-coated mycophenolate sodium + corticosteroids + induction therapy with basiliximab. Starting dose of tacrolimus was 0.15 mg/kg/day, adjusted to target trough levels (C0) of 8–12 ng/mL from Tx to month (M) 1; 5–10 ng/mL up to M3; and 5–8 ng/mL up to M6. Primary objective (phase I) was to demonstrate comparable PK of tacrolimus Hexal® vs Prograf® as assessed by the ratio of the AUC0-12h over a period of 1-M post-Tx. Here we present the PK results at M1 along with efficacy and safety data at M6.

Results: Of 76 patients, 44 patients had an evaluable PK profile on Day 3, 10 and M1 and were included in PK analysis (tacrolimus Hexal®, n=23; Prograf®, n=21). A total of 73 patients were included in safety analysis (tacrolimus Hexal®, n=35; Prograf®, n=38). At M1, PK parameters: dose-normalized tacrolimus 12-h-AUC (h/103xL), Cmax (1/103xL), and mean 12-h tacrolimus C0 ([mu]g/L) were comparable between the treatment arms. At M6, tacrolimus Hexal® vs Prograf® had comparable incidence of composite events and its individual components (biopsy-proven acute rejection, graft loss, or death). Incidence of adverse events (AEs) and serious AEs were comparable between the treatment groups.

Conclusion: Tacrolimus Hexal® and Prograf® in de novo KTxR had a similar PK profile with comparable efficacy and safety.

CITATION INFORMATION: Arns W, Huppertz A, Rath T, Ziefle S, Rump L, Hansen A, Baeumer D, Budde K, Lehner L, Klein T, Schenker P. Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Arns W, Huppertz A, Rath T, Ziefle S, Rump L, Hansen A, Baeumer D, Budde K, Lehner L, Klein T, Schenker P. Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-pharmacokinetic-and-clinical-outcomes-of-tacrolimus-hexal-with-prograf-based-regimen-in-de-novo-kidney-transplant-recipients-results-from-the-randomized-spartacus-study/. Accessed April 23, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Deceased Non-A2 Donor ABO-Incompatible Liver Transplantation – Promising Results with Anti-A/B Antibody Reduction Both Pre- and Post-Transplant.
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.